# Comparison of sexual function after robot-assisted radical prostatectomy and carbon-ion radiotherapy for Japanese prostate cancer patients using propensity score matching

**Authors:** Yoshiyuki Miyazawa, Hidekazu Koike, Daisuke Oka, Hidemasa Kawamura, Nobuteru Kubo, Yuhei Miyasaka, Masahiro Onishi, Takahiro Syuto, Yoshitaka Sekine, Hiroshi Matsui, Tatsuya Ohno, Kazuhiro Suzuki

PMC · DOI: 10.1186/s12885-024-12062-7 · BMC Cancer · 2024-03-05

## TL;DR

This study compares sexual function outcomes in Japanese prostate cancer patients treated with robot-assisted surgery or carbon-ion radiotherapy.

## Contribution

The study provides new evidence on sexual function preservation in prostate cancer patients using propensity score matching in Japan.

## Key findings

- CIRT preserved sexual function better than RARP, with smaller decreases in EPIC scores.
- Both treatments caused significant declines in sexual function scores over 24 months.
- Propensity score matching revealed significant differences in sexual function outcomes between the two treatments.

## Abstract

The quality of life of patients is an important consideration when selecting treatments for localized prostate cancer (PCa). We retrospectively compared sexual function after robot-assisted radical prostatectomy (RARP) and carbon-ion radiotherapy (CIRT) using propensity score matching.

In total, 127 Japanese PCa patients treated with RARP and 190 treated with CIRT monotherapy were evaluated. We evaluated the Expanded Prostate Cancer Index Composite (EPIC) score before treatment and 12 and 24 months after treatment. After propensity score matching, data from 101 patients from each group were analyzed. The study protocol was approved by the Institutional Review Board of Gunma University Hospital (no. IRB2020-050, 1839).

After propensity score matching, the mean EPIC sexual function summary scores in the RARP and CIRT groups were 46.4 and 48.2, respectively. At 12 and 24 months after treatment, these scores were 27.9 (39.9% decrease) and 28.2 (39.2% decrease) in the RARP group and 41.4 (14.1% decrease) and 41.6 (13.7% decrease) in the CIRT group, respectively. Both groups demonstrated significantly decreased scores after 12 and 24 months of treatment compared to before treatment (all p < 0.05). At 12 and 24 months, the sexual function summary score was significantly higher in the CIRT group than in the RARP group (p < 0.001).

There was a smaller decrease in the EPIC sexual function score in the CIRT group than in the RARP group. These results provide useful information for treatment decision-making of Japanese PCa patients.

## Linked entities

- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Diseases:** PCa (MESH:D011471)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10916055/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10916055/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC10916055/full.md

---
Source: https://tomesphere.com/paper/PMC10916055